‘In the current 28 Member States of the European Union (EU), approximately 34,000 new cases of cervical cancer and 13,000 deaths occur' [Ferlay et al.: Eur J Cancer 2014;49:1374-1403]. ‘The current 10-fold gradient in the mortality rates of cervical cancer among the EU Member States largely reflects the persistent absence, or inadequate implementation of cervical cancer screening programmes more than 10 years after organized, population-based screening programmes following European quality assurance guidelines were unanimously recommended by the Health Ministers of the EU' [Council of the European Union: Off J Eur Union 2003;327:34-38]. This article will compare the strengths, weaknesses and risks of the following 4 cervical health screening strategies: HPV as a triage of cytology, cytology as a triage of HPV, cotesting (parallel) or cytology at the time of HPV (HPV-informed guided screening). ‘The optimal screening strategy should identify those cervical cancer precursors likely to progress to invasive cancers (maximizing the benefits of screening) and avoid the detection and unnecessary treatment of transient HPV infection and its associated benign lesions that are not destined to become cancerous (minimizing the potential harms of screening)' [Saslow et al.: Am J Clin Pathol 2012;137:516-542].

1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F: Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2014;49:1374-1403.
2.
Council of the European Union: Council recommendation of 2 December 2003 on cancer screening (2003/878/EC). Off J Eur Union 2003;327:34-38.
3.
Walboomers J, Jacobs M, Manos M, Bosch X, Kummer J, Shah K, Snijders PJ, Peto J, Meijer CJ, Muñoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
4.
Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJF, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer C; International HPV Working Group: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
5.
Blatt A, Kennedy R, Luff R, Austin RM, Rabin D: Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer Cytopathol 2015;123:282-288.
6.
Zheng B, Li Z, Griffith C, Yan S, Chen C, Ding X, Liang X, Yang H, Zhao C: Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China's largest CAP-certified laboratory. Cancer Cytopathol 2015;123:428-434.
7.
Tao X, Griffith C, Zhou X, Wang Z, Yan Y, Li Z, Zhao C: History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China. Cancer Cytopathol 2015;123:421-427.
8.
Bekker JB, John TS, Leiman G: Confirming suboptimal adherence to HPV cotesting guidelines in an academic center in Vermont. Am J Clin Pathol 2013;139:259-260.
9.
Tatsas AD, Phelan DF, Gravitt PE, Boitnott JK, Clark DP: Practice patterns in cervical cancer screening and human papillomavirus testing. Am J Clin Pathol 2012;138:223-229.
10.
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER; ACS-ASCCP-ASCP Cervical Cancer Guideline Committee: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol 2012;137:516-542.
11.
Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D: 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-222.
12.
Rebolj M, Bonde J, Preisler S, Ejegod D, Rygaard C, Lynge E: Differential detection of human papillomavirus genotypes and cervical intraepithelial neoplasia by four commercial assays. J Clin Microbiol 2016, DOI: 10.1128/JCM.01321-16.
13.
Tjalma W, Depuydt C: Don't forget HPV-45 in cervical cancer screening. Am J Clin Pathol 2012;137:161-166.
14.
Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Dürst M, Schneider A, von Knebel Doeberitz M: Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008;68:307-313.
15.
Badaracco G, Venuti A, Sedati A, Marcante ML: HPV16 and HPV18 in genital tumors: significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 2002;67:574-582.
16.
Pett M, Coleman N: Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007;212:356-367.
17.
Tjalma W, Fiander A, Reich O, Powell N, Nowakowski AM, Kirschner B, Koiss R, O'Leary J, Joura EA, Rosenlund M, Colau B, Schledermann D, Kukk K, Damaskou V, Repanti M, Vladareanu R, Kolomiets L, Savicheva A, Shipitsyna E, Ordi J, Molijn A, Quint W, Raillard A, Rosillon D, De Souza SC, Jenkins D, Holl K; HERACLES/SCALE Study Group: Human papillomavirus type distribution in cervical neoplasia: results from two parallel epidemiological studies in women with high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe (abstract 766). International Papilloma Virus Conference, Montreal, July 2010.
18.
De Sanjose S, Quint WGV, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, Banjo A, Menéndez C, Domingo EJ, Velasco J, et al: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048-1056.
19.
Munoz N, Bosch X, de Sanjose S, Herrero R, Castellsague X, Shah K, Snijders P, Meijer C: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
20.
Insigna R, Perez G, Wheeler C, Koutsky L, Garland S, Leodolter S, Joura E, Ferris D, Steben M, Brown D, Elbasha E, Paavonen J, Haupt RM; FUTURE I Investigators: Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol Biomarkers Prev 2010;19:1585-1594.
21.
Center for Disease Control and Prevention (CDC): Human papillomavirus-associated cancers - United States, 2004-2008. MMWR 2012;61:261.
22.
23.
Baseman JG, Kulasingam SL, Harris TG, Hughes JP, Kiviat NB, Mao C, Koutsky LA: Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. Am J Obstetr Gynecol 2008;26.e1-e8.
24.
Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC Jr, Cuzick J; ATHENA HPV Study Group: Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013;208:184.e1-e11.
25.
Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders P, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer C; International HPV screening working group: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-532.
26.
Sideri M: HPV-based screening for prevention of cervical cancer. Lancet 2014;383:1294.
27.
Sasieni P: Eurogin 2016 Abstract - Triaging Methods after a Positive HPV Test for Cervical Cancer Screening: Cytology. London, Queen Mary University of London, 2016.
28.
Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE: Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011;12:663-672.
29.
Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK: Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014;106:dju153.
30.
Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW, Heideman DA, Kenter GG, Cuzick J, Snijders PJ, Meijer CJ: Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
31.
Pan Q, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, Cao J, Jiang Y, Zhao FH, Qiao YL: Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. Gynecol Oncol 2014;133:172-179.
32.
Benoy I, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, Temmerman M, Depuydt CE: Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. Am J Obstet Gynecol 2011;205:569.
33.
34.
Felix J, Lacey MJ, Miller JD, Lenhart GM, Spitzer M, Kulkarni R: The clinical and economic benefits of co-testing versus primary HPV testing for cervical cancer screening: a modeling analysis. J Womens Health 2016;25:606-616.
35.
Lynge E, Tornberg S, von Karsa L, Segnan N, van Delden JJ: Determinants of successful implementation of population-based cancer screening programmes. Eur J Cancer 2012;48:743-748.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.